Spinal Muscular Atrophy

Global Market Trajectory & Analytics

MCP16044

EXECUTIVE ENGAGEMENTS

POOL

682
Number of executives repeatedly engaged by snail & email outreach

INTERACTIONS

136
Interactions with Platform & by Email

PARTICIPANTS

27
Unique # Participated

VALIDATIONS

11
Responses Validated*

COMPANIES

31
Responses Validated*
* Login for a full stack data experience

DATE

APR 2021

TABLES

60

PAGES

121

EDITION

7

PRICE

USD 4950

CODE

MCP16044


COMPETITIVE METRICS

COMPANY

D S N T

% *

Accomable

AveXis

BraunAbility

Cytokinetics, Inc.

F. Hoffmann-La Roche AG

Gwendolyn Strong Foundation (theGSF)

Ionis Pharmaceuticals, Inc.

Novartis International AG

Reborna Biosciences

Scholar Rock

View More...

SUBMIT
Note: Best viewed in Landscape Mode
  

HIGHLIGHTS & REPORT INDEX

Amid the COVID-19 crisis, the global market for Spinal Muscular Atrophy estimated at US$1.1 Billion in the year 2020, is projected to reach a revised size of US$2.5 Billion by 2027, growing at a CAGR of 12.2% over the analysis period 2020-2027. Type 1, one of the segments analyzed in the report, is projected to record a 12.9% CAGR and reach US$1.5 Billion by the end of the analysis period. After an early analysis of the business implications of the pandemic and its induced economic crisis, growth in the Type 2 segment is readjusted to a revised 11.7% CAGR for the next 7-year period.
The Spinal Muscular Atrophy market in the U.S. is estimated at US$323.3 Million in the year 2020. China, the world`s second largest economy, is forecast to reach a projected market size of US$428.3 Million by the year 2027 trailing a CAGR of 11.7% over the analysis period 2020 to 2027. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at 10.8% and 10.3% respectively over the 2020-2027 period. Within Europe, Germany is forecast to grow at approximately 8.8% CAGR.
In the global Type 3 segment, USA, Canada, Japan, China and Europe will drive the 10.8% CAGR estimated for this segment. These regional markets accounting for a combined market size of US$107.6 Million in the year 2020 will reach a projected size of US$220.7 Million by the close of the analysis period. China will remain among the fastest growing in this cluster of regional markets. Led by countries such as Australia, India, and South Korea, the market in Asia-Pacific is forecast to reach US$289.7 Million by the year 2027.

SELECT PLAYERS

AveXis, Inc.; Biogen Inc.; Cytokinetics, Inc.; F. Hoffmann-La Roche AG; Ionis Pharmaceuticals, Inc.; Novartis AG; Pfizer Inc.

SEGMENTS

» Segment (Type 1, Type 2, Type 3, Type 4)

GEOGRAPHIES

» World » United States » Canada » Japan » China » Europe » France » Germany » Italy » United Kingdom » and Rest of Europe » Asia-Pacific » Rest of World

TABLE OF CONTENTS

1. MARKET OVERVIEW
Influencer Market Insights
World Market Trajectories
Impact of Covid-19 and a Looming Global Recession
2. FOCUS ON SELECT PLAYERS
3. MARKET TRENDS & DRIVERS
4. GLOBAL MARKET PERSPECTIVE
World Current & Future Analysis for Spinal Muscular Atrophy by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2020 through 2027 and % CAGR
World Historic Review for Spinal Muscular Atrophy by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
World 15-Year Perspective for Spinal Muscular Atrophy by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets for Years 2012, 2020 & 2027
World Current & Future Analysis for Type 1 by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2020 through 2027 and % CAGR
World Historic Review for Type 1 by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
World 15-Year Perspective for Type 1 by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2012, 2020 & 2027
World Current & Future Analysis for Type 2 by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2020 through 2027 and % CAGR
World Historic Review for Type 2 by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
World 15-Year Perspective for Type 2 by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2012, 2020 & 2027
World Current & Future Analysis for Type 3 by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2020 through 2027 and % CAGR
World Historic Review for Type 3 by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
World 15-Year Perspective for Type 3 by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2012, 2020 & 2027
World Current & Future Analysis for Type 4 by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2020 through 2027 and % CAGR
World Historic Review for Type 4 by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
World 15-Year Perspective for Type 4 by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2012, 2020 & 2027
UNITED STATES
USA Current & Future Analysis for Spinal Muscular Atrophy by Segment - Type 1, Type 2, Type 3 and Type 4 - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
USA Historic Review for Spinal Muscular Atrophy by Segment - Type 1, Type 2, Type 3 and Type 4 Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
USA 15-Year Perspective for Spinal Muscular Atrophy by Segment - Percentage Breakdown of Value Sales for Type 1, Type 2, Type 3 and Type 4 for the Years 2012, 2020 & 2027
CANADA
Canada Current & Future Analysis for Spinal Muscular Atrophy by Segment - Type 1, Type 2, Type 3 and Type 4 - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
Canada Historic Review for Spinal Muscular Atrophy by Segment - Type 1, Type 2, Type 3 and Type 4 Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
Canada 15-Year Perspective for Spinal Muscular Atrophy by Segment - Percentage Breakdown of Value Sales for Type 1, Type 2, Type 3 and Type 4 for the Years 2012, 2020 & 2027
JAPAN
Japan Current & Future Analysis for Spinal Muscular Atrophy by Segment - Type 1, Type 2, Type 3 and Type 4 - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
Japan Historic Review for Spinal Muscular Atrophy by Segment - Type 1, Type 2, Type 3 and Type 4 Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
Japan 15-Year Perspective for Spinal Muscular Atrophy by Segment - Percentage Breakdown of Value Sales for Type 1, Type 2, Type 3 and Type 4 for the Years 2012, 2020 & 2027
CHINA
China Current & Future Analysis for Spinal Muscular Atrophy by Segment - Type 1, Type 2, Type 3 and Type 4 - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
China Historic Review for Spinal Muscular Atrophy by Segment - Type 1, Type 2, Type 3 and Type 4 Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
China 15-Year Perspective for Spinal Muscular Atrophy by Segment - Percentage Breakdown of Value Sales for Type 1, Type 2, Type 3 and Type 4 for the Years 2012, 2020 & 2027
EUROPE
Europe Current & Future Analysis for Spinal Muscular Atrophy by Geographic Region - France, Germany, Italy, UK and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2020 through 2027 and % CAGR
Europe Historic Review for Spinal Muscular Atrophy by Geographic Region - France, Germany, Italy, UK and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
Europe 15-Year Perspective for Spinal Muscular Atrophy by Geographic Region - Percentage Breakdown of Value Sales for France, Germany, Italy, UK and Rest of Europe Markets for Years 2012, 2020 & 2027
Europe Current & Future Analysis for Spinal Muscular Atrophy by Segment - Type 1, Type 2, Type 3 and Type 4 - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
Europe Historic Review for Spinal Muscular Atrophy by Segment - Type 1, Type 2, Type 3 and Type 4 Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
Europe 15-Year Perspective for Spinal Muscular Atrophy by Segment - Percentage Breakdown of Value Sales for Type 1, Type 2, Type 3 and Type 4 for the Years 2012, 2020 & 2027
FRANCE
France Current & Future Analysis for Spinal Muscular Atrophy by Segment - Type 1, Type 2, Type 3 and Type 4 - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
France Historic Review for Spinal Muscular Atrophy by Segment - Type 1, Type 2, Type 3 and Type 4 Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
France 15-Year Perspective for Spinal Muscular Atrophy by Segment - Percentage Breakdown of Value Sales for Type 1, Type 2, Type 3 and Type 4 for the Years 2012, 2020 & 2027
GERMANY
Germany Current & Future Analysis for Spinal Muscular Atrophy by Segment - Type 1, Type 2, Type 3 and Type 4 - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
Germany Historic Review for Spinal Muscular Atrophy by Segment - Type 1, Type 2, Type 3 and Type 4 Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
Germany 15-Year Perspective for Spinal Muscular Atrophy by Segment - Percentage Breakdown of Value Sales for Type 1, Type 2, Type 3 and Type 4 for the Years 2012, 2020 & 2027
ITALY
Italy Current & Future Analysis for Spinal Muscular Atrophy by Segment - Type 1, Type 2, Type 3 and Type 4 - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
Italy Historic Review for Spinal Muscular Atrophy by Segment - Type 1, Type 2, Type 3 and Type 4 Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
Italy 15-Year Perspective for Spinal Muscular Atrophy by Segment - Percentage Breakdown of Value Sales for Type 1, Type 2, Type 3 and Type 4 for the Years 2012, 2020 & 2027
UNITED KINGDOM
UK Current & Future Analysis for Spinal Muscular Atrophy by Segment - Type 1, Type 2, Type 3 and Type 4 - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
UK Historic Review for Spinal Muscular Atrophy by Segment - Type 1, Type 2, Type 3 and Type 4 Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
UK 15-Year Perspective for Spinal Muscular Atrophy by Segment - Percentage Breakdown of Value Sales for Type 1, Type 2, Type 3 and Type 4 for the Years 2012, 2020 & 2027
REST OF EUROPE
Rest of Europe Current & Future Analysis for Spinal Muscular Atrophy by Segment - Type 1, Type 2, Type 3 and Type 4 - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
Rest of Europe Historic Review for Spinal Muscular Atrophy by Segment - Type 1, Type 2, Type 3 and Type 4 Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
Rest of Europe 15-Year Perspective for Spinal Muscular Atrophy by Segment - Percentage Breakdown of Value Sales for Type 1, Type 2, Type 3 and Type 4 for the Years 2012, 2020 & 2027
ASIA-PACIFIC
Asia-Pacific Current & Future Analysis for Spinal Muscular Atrophy by Segment - Type 1, Type 2, Type 3 and Type 4 - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
Asia-Pacific Historic Review for Spinal Muscular Atrophy by Segment - Type 1, Type 2, Type 3 and Type 4 Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
Asia-Pacific 15-Year Perspective for Spinal Muscular Atrophy by Segment - Percentage Breakdown of Value Sales for Type 1, Type 2, Type 3 and Type 4 for the Years 2012, 2020 & 2027
REST OF WORLD
Rest of World Current & Future Analysis for Spinal Muscular Atrophy by Segment - Type 1, Type 2, Type 3 and Type 4 - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
Rest of World Historic Review for Spinal Muscular Atrophy by Segment - Type 1, Type 2, Type 3 and Type 4 Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
Rest of World 15-Year Perspective for Spinal Muscular Atrophy by Segment - Percentage Breakdown of Value Sales for Type 1, Type 2, Type 3 and Type 4 for the Years 2012, 2020 & 2027
Total Companies Profiled: 31

PREVIEW REPORT

YOUR PRIVACY MATTERS!

Our robust permission-based engagement strategy requires a one-time double opt-in and/or re-consent for all users. We will re-establish consent once a year from date of last use. Both these practices exceed GDPR mandates.

What we store: Primary coordinates such as email, company address and phone. In-house developed influencer rank.
How we store: Encrypted and additionally secured by firewalls.
How we use your data: Only to contact you directly. We never share your coordinates with any individual or entity outside our company for any reason.
Privacy queries: Privacy@StrategyR.com